p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.

Fourteen Non-Hodgkin's lymphoma cell lines were generated and assessed for the presence of structural p53, c-myc and bcl-2 gene changes. Single or multiple changes were observed in 11 of the lines. Alterations of the p53 gene were most frequent and documented for 10 lines by immunoprecipitation using the antibodies PAb 240 and PAb 1801, sequencing studies and Southern blot analysis. A detailed study was performed in one of the cell lines (OCI-Ly 4) for which material of the original tumor sample was available. Two point mutations identified by sequencing cDNA derived from the cell line were also present in the original tumor specimen. In contrast, DNA prepared from fibroblasts of the same patient did not show the mutations. Six of the 14 lines demonstrated c-myc rearrangements, while bcl-2 changes were observed in 4. The presence of c-myc was associated with shorter survival of this group of patients with aggressive disease. None of the other changes present as single or composite alterations were correlated with clinical outcome measures.

[1]  M. Minden,et al.  Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. , 1994, Blood.

[2]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Yi-Song Wang,et al.  Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[4]  X. H. Wang,et al.  Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia. , 1992, Leukemia & lymphoma.

[5]  M. Minden,et al.  Growth of human lymphoma cells in SCID mice. , 1992, Leukemia & lymphoma.

[6]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[7]  X. H. Wang,et al.  A human lymphoma cell line with multiple immunoglobulin rearrangements. , 1992, The Journal of clinical investigation.

[8]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[9]  T. Crook,et al.  p53 is frequently mutated in Burkitt's lymphoma cell lines. , 1991, The EMBO journal.

[10]  K. Magnússon,et al.  Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. , 1991, Oncogene.

[11]  I. Weissman,et al.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.

[12]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Minden,et al.  Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.

[14]  T. Hunter.  Cooperation between oncogenes , 1991, Cell.

[15]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[16]  D. Slamon,et al.  Frequency and structure of p53 rearrangements in human osteosarcoma. , 1990, Cancer research.

[17]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[18]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[19]  T. Pawson,et al.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene , 1989, Molecular and cellular biology.

[20]  X. H. Wang,et al.  A possible autocrine role for interleukin-6 in two lymphoma cell lines. , 1989, Blood.

[21]  R. Weinberg,et al.  Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. , 1989, Cancer research.

[22]  H. Koeffler,et al.  Rearrangement of the p53 gene in human osteogenic sarcomas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Minden,et al.  The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. , 1987, Blood.

[24]  D. Pim,et al.  Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.

[25]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[26]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Gelmann,et al.  Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Pim,et al.  Monoclonal antibodies specific for simian virus 40 tumor antigens , 1981, Journal of virology.

[29]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[30]  E. Lehmann,et al.  Nonparametrics: Statistical Methods Based on Ranks , 1976 .

[31]  N. Berinstein,et al.  Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.

[32]  J. Lotem,et al.  Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[34]  S. Cory,et al.  Oncogene co-operation in leukaemogenesis. , 1992, Cancer surveys.

[35]  H. Toutenburg,et al.  Lehmann, E. L., Nonparametrics: Statistical Methods Based on Ranks, San Francisco. Holden‐Day, Inc., 1975. 480 S., $ 22.95 . , 1977 .